In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will obtain treatment until ailment progression or perhaps the individuals are not able to tolerate the study drugs. Total, our present work highlights the potential utilization of ARV-825 in combination https://brd4-targeted-therapy-abb34679.wssblogs.com/31978976/considerations-to-know-about-is-abbv-744-effective-for-hematologic-cancers